{"transactions":[{"id":720705,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true}}],"security":"Share Option (Right to Buy)","published_at":"2026-07-01T20:07:04.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Share options vest in twelve equal monthly installments commencing on July 29, 2026."}],"balance_after":47500,"derivative":{"exercise_price":1.61,"expiration_date":"2036-06-29","underlying":"American Depositary Shares","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001730463-26-000093","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000173046326000093/form4.xml","form_type":"4"}},{"id":720704,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true}}],"security":"Restricted Share Units","published_at":"2026-07-01T20:07:04.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in one installment on June 29, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in one installment on June 29, 2027."}],"balance_after":31667,"derivative":{"underlying":"American Depositary Shares","underlying_shares":31667},"source":{"system":"sec-edgar","filing":"0001730463-26-000093","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000173046326000093/form4.xml","form_type":"4"}},{"id":729235,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T22:10:39.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":35910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":35910,"derivative":{"exercise_price":27.97,"expiration_date":"2036-06-19","underlying":"Common Stock","underlying_shares":35910},"source":{"system":"sec-edgar","filing":"0001193125-26-279871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279871/ownership.xml","form_type":"4"}},{"id":729234,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T22:10:39.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":5740,"source":{"system":"sec-edgar","filing":"0001193125-26-279871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279871/ownership.xml","form_type":"4"}},{"id":750797,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:43.000Z","date":"2026-06-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.08,"value":38808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":112805,"source":{"system":"sec-edgar","filing":"0001628280-26-040493","document":"wk-form4_1780520620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828026040493/wk-form4_1780520620.xml","form_type":"4"}},{"id":750796,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T21:03:43.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.  Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":125405,"source":{"system":"sec-edgar","filing":"0001628280-26-040493","document":"wk-form4_1780520620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828026040493/wk-form4_1780520620.xml","form_type":"4"}},{"id":791130,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:08:07.000Z","date":"2026-05-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1697,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."}],"balance_after":0,"derivative":{"exercise_price":34.6,"underlying":"Common Stock","underlying_shares":1697},"source":{"system":"sec-edgar","filing":"0001656998-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000165699826000006/primarydocument.xml","form_type":"4"}},{"id":791129,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:08:07.000Z","date":"2026-05-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."}],"balance_after":0,"derivative":{"exercise_price":4.13,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001656998-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000165699826000006/primarydocument.xml","form_type":"4"}},{"id":924474,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T23:06:50.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":1697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $45,000 for 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2026, such that 100% of the shares subject to the option will be fully vested on January 1, 2027."}],"balance_after":1697,"derivative":{"exercise_price":34.6,"expiration_date":"2036-01-31","underlying":"Common Stock","underlying_shares":1697},"source":{"system":"sec-edgar","filing":"0001656998-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000165699826000002/primarydocument.xml","form_type":"4"}},{"id":1006368,"issuer":{"id":3014,"kind":"organization","name":"CARDINAL HEALTH INC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-06T21:09:12.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":1067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted share units that will vest on November 5, 2026, except if the 2026 Annual Meeting of Shareholders is prior to November 5, 2026, then the restricted share units will vest on the date of the 2026 Annual Meeting of Shareholders."}],"balance_after":4085,"source":{"system":"sec-edgar","filing":"0001656998-25-000004","document":"wk-form4_1762463303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/721371/000165699825000004/wk-form4_1762463303.xml","form_type":"4"}},{"id":1107437,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-17T21:00:08.000Z","date":"2025-06-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":12600,"price":3.58,"value":45108.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":80405,"source":{"system":"sec-edgar","filing":"0001628280-25-031890","document":"wk-form4_1750193999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828025031890/wk-form4_1750193999.xml","form_type":"4"}},{"id":1120876,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-05T21:10:51.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's\ncontinued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":93005,"source":{"system":"sec-edgar","filing":"0001628280-25-029736","document":"wk-form4_1749157790.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828025029736/wk-form4_1749157790.xml","form_type":"4"}},{"id":1248837,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-24T23:05:02.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares subject to the option vest on the first anniversary measured from February 20, 2025 (the \"Vesting Commencement Date\"), and 1/36th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date."}],"balance_after":90000,"derivative":{"exercise_price":4.13,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001562180-25-001542","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000156218025001542/primarydocument.xml","form_type":"4"}},{"id":1373706,"issuer":{"id":3014,"kind":"organization","name":"CARDINAL HEALTH INC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-07T21:51:19.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":1730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted share units that will vest on November 6, 2025, except if the 2025 Annual Meeting of Shareholders is prior to November 6, 2025, then the restricted share units will vest on the date of the 2025 Annual Meeting of Shareholders."}],"balance_after":3018,"source":{"system":"sec-edgar","filing":"0000721371-24-000152","document":"wk-form4_1731015972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000152/wk-form4_1731015972.xml","form_type":"4"}},{"id":1474541,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-19T01:45:33.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":6995,"price":2.89,"value":20215.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units."}],"balance_after":53005,"source":{"system":"sec-edgar","filing":"0001628280-24-028993","document":"wk-form4_1718761526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828024028993/wk-form4_1718761526.xml","form_type":"4"}},{"id":1478450,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-06-14T21:46:59.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001628280-24-028357","document":"wk-form4_1718401609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000162828024028357/wk-form4_1718401609.xml","form_type":"4"}},{"id":1573835,"issuer":{"id":3014,"kind":"organization","name":"CARDINAL HEALTH INC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-03-18T21:48:17.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":1288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted share units that will vest on March 15, 2025."}],"balance_after":1288,"source":{"system":"sec-edgar","filing":"0000721371-24-000019","document":"wk-form4_1710798486.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000019/wk-form4_1710798486.xml","form_type":"4"}},{"id":1809763,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:04:56.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 10, 2024.  Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 10, 2024.  Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 10, 2024.  Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-23-045412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045412/doc4.xml","form_type":"4"}},{"id":1809762,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:04:56.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28200,"price":18.4,"value":518880.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option award, which provided for ratable vesting in 36 monthly installments beginning on May 10, 2023, became fully vested and was canceled upon effectiveness of the Merger (defined in the Remarks below), and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one contingent value right (\"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the contingent value rights agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":21.6,"expiration_date":"2033-04-09","underlying":"Common Stock","underlying_shares":28200},"source":{"system":"sec-edgar","filing":"0001209191-23-045412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045412/doc4.xml","form_type":"4"}},{"id":1920882,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock (RSU)(Common Stock)","published_at":"2023-04-12T16:59:21.000Z","date":"2023-04-10","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on April 10, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":7000,"derivative":{"expiration_date":"2026-04-10","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-23-024111","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123024111/doc4.xml","form_type":"4"}},{"id":1920881,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-12T16:59:21.000Z","date":"2023-04-10","kind":"grant","planned":false,"acquired":true,"shares":28200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option fully vests as to 1/36 of the total shares monthly beginning on May 10, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":28200,"derivative":{"exercise_price":21.6,"expiration_date":"2033-04-09","underlying":"Common Stock","underlying_shares":28200},"source":{"system":"sec-edgar","filing":"0001209191-23-024111","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123024111/doc4.xml","form_type":"4"}},{"id":2126812,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-02T23:09:49.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the \"2022 Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date."}],"balance_after":500000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-10-30","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-22-055407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000120919122055407/doc4.xml","form_type":"4"}},{"id":2420840,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-31T22:13:59.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022."}],"balance_after":500000,"derivative":{"exercise_price":8.21,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-22-005647","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656998/000120919122005647/doc4.xml","form_type":"4"}},{"id":2671811,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T21:07:52.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":42223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on the one-year anniversary of the date of grant."}],"balance_after":42223,"derivative":{"exercise_price":5.97,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":42223},"source":{"system":"sec-edgar","filing":"0000899243-21-023435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924321023435/doc4.xml","form_type":"4"}},{"id":3001155,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-10-23T17:34:34.000Z","date":"2020-10-23","kind":"disposition_to_issuer","acquired":false,"shares":3718,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3718},"source":{"system":"sec-edgar","filing":"0001104659-20-117802","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920117802/a4.xml","form_type":"4"}},{"id":3001154,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-23T17:34:34.000Z","date":"2020-10-23","kind":"disposition_to_issuer","acquired":false,"shares":29040,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":29040},"source":{"system":"sec-edgar","filing":"0001104659-20-117802","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920117802/a4.xml","form_type":"4"}},{"id":3103706,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T17:19:07.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":6540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":6540,"derivative":{"exercise_price":33.62,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock, par value $0.01 per share","underlying_shares":6540},"source":{"system":"sec-edgar","filing":"0001104659-20-075692","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920075692/a4.xml","form_type":"4"}},{"id":3103705,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2020-06-22T17:19:07.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":3718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":3718,"source":{"system":"sec-edgar","filing":"0001104659-20-075692","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920075692/a4.xml","form_type":"4"}},{"id":3120306,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T16:55:10.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":40138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant."}],"balance_after":40138,"derivative":{"exercise_price":6.48,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":40138},"source":{"system":"sec-edgar","filing":"0000899243-20-015491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924320015491/doc4.xml","form_type":"4"}},{"id":3245191,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-02-27T16:48:05.000Z","date":"2020-02-26","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest in full on the first anniversary of the date of grant, provided that the reporting person remains a director on such date."}],"balance_after":22500,"derivative":{"exercise_price":16.36,"exercise_date":"2021-02-26","expiration_date":"2027-02-26","underlying":"Common Stock, par value $0.01 per share","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001104659-20-026244","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920026244/a4.xml","form_type":"4"}},{"id":3388561,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T18:52:57.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On June 13, 2018, the Reporting Person was granted an option to purchase 150,000 shares of Issuer's Common Stock (the \"Option\"). The Option vests upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the \"FDA\") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the \"FDA Filing Milestone\"). On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 150,000 shares subject to the Option."}],"balance_after":0,"derivative":{"exercise_price":16.2,"exercise_date":"2019-04-23","expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-053904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053904/doc4.xml","form_type":"4"}},{"id":3388560,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2019-10-24T18:52:57.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to the Reporting Person providing continuous service to the Issuer, 25% of the shares subject to the RSU shall vest on each annual anniversary of January 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this RSU, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to the product of (A) $18.00 and (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this RSU, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Subject to the Reporting Person providing continuous service to the Issuer, 25% of the shares subject to the RSU shall vest on each annual anniversary of January 1, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-053904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053904/doc4.xml","form_type":"4"}},{"id":3388559,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T18:52:57.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":505000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":505000},"source":{"system":"sec-edgar","filing":"0001209191-19-053904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053904/doc4.xml","form_type":"4"}},{"id":3388558,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T18:52:57.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of June 13, 2018 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"derivative":{"exercise_price":16.2,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001209191-19-053904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053904/doc4.xml","form_type":"4"}},{"id":3497111,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-07T16:46:52.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":28882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant."}],"balance_after":28882,"derivative":{"exercise_price":14.66,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":28882},"source":{"system":"sec-edgar","filing":"0000899243-19-016038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319016038/doc4.xml","form_type":"4"}},{"id":3548636,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-25T18:56:21.000Z","date":"2019-04-23","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 13, 2018, the Reporting Person was granted an option to purchase 150,000 shares of Issuer's Common Stock (the \"Option\"). The Option vests upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the \"FDA\") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the \"FDA Filing Milestone\"). On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 150,000 shares subject to the Option."}],"balance_after":150000,"derivative":{"exercise_price":16.2,"exercise_date":"2019-04-23","expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-026038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119026038/doc4.xml","form_type":"4"}},{"id":3667950,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2019-02-08T16:40:00.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person providing continuous service to the Issuer, 25% of the shares subject to the RSU shall vest on each annual anniversary of January 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person providing continuous service to the Issuer, 25% of the shares subject to the RSU shall vest on each annual anniversary of January 1, 2019."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-008551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119008551/doc4.xml","form_type":"4"}},{"id":3667949,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T16:40:00.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":505000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":505000,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":505000},"source":{"system":"sec-edgar","filing":"0001209191-19-008551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119008551/doc4.xml","form_type":"4"}},{"id":3790639,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-15T18:44:21.000Z","date":"2018-10-11","kind":"grant","acquired":true,"shares":25848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant."}],"balance_after":25848,"derivative":{"exercise_price":27.92,"expiration_date":"2028-10-11","underlying":"Common Stock","underlying_shares":25848},"source":{"system":"sec-edgar","filing":"0000899243-18-026717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924318026717/doc4.xml","form_type":"4"}},{"id":3892449,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T16:02:19.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of June 13, 2018 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":1000000,"derivative":{"exercise_price":16.2,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001209191-18-038016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118038016/doc4.xml","form_type":"4"}},{"id":3998155,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:31.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":13927,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the offer price of $10.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the offer price of $10.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13927},"source":{"system":"sec-edgar","filing":"0000899243-18-007302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007302/doc4.xml","form_type":"4"}},{"id":3998154,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:31.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":12437,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the \"Merger Agreement\"), the restricted stock units were cancelled in exchange for a cash payment of $124,370.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the offer price of $10.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the \"Merger Agreement\"), the restricted stock units were cancelled in exchange for a cash payment of $124,370.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the offer price of $10.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on April 3, 2017 and vest on the one-year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12437},"source":{"system":"sec-edgar","filing":"0000899243-18-007302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007302/doc4.xml","form_type":"4"}},{"id":4007513,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":98545,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":98545},"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4007512,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":30002,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":25.29,"expiration_date":"2026-11-07","underlying":"Common Stock","underlying_shares":30002},"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4007511,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":93294,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":51.76,"expiration_date":"2025-10-31","underlying":"Common Stock","underlying_shares":93294},"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4007510,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":35893,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents performance-based restricted stock awards (\"PSAs\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4007509,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":25639,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":35893,"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4007508,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":20580,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":61532,"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4007507,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-07T18:13:04.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":82112,"source":{"system":"sec-edgar","filing":"0001209191-18-017797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118017797/doc4.xml","form_type":"4"}},{"id":4054192,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-15T19:31:32.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":4159,"price":85.55,"value":355802.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the number of shares sold, as reported on the Form 4 filed February 14, 2018."}],"balance_after":89612,"source":{"system":"sec-edgar","filing":"0001209191-18-010536","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118010536/doc4a.xml","form_type":"4/A","original_submission_date":"2018-02-14"}},{"id":4057094,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-14T19:24:50.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":4157,"price":85.55,"value":355631.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":89614,"source":{"system":"sec-edgar","filing":"0001209191-18-010186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118010186/doc4.xml","form_type":"4"}},{"id":4068126,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-09T19:27:23.000Z","date":"2018-02-08","kind":"exercise","acquired":false,"shares":2663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":98545,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":2663},"source":{"system":"sec-edgar","filing":"0001209191-18-009012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118009012/doc4.xml","form_type":"4"}},{"id":4068125,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-09T19:27:23.000Z","date":"2018-02-08","kind":"exercise","acquired":false,"shares":834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":30002,"derivative":{"exercise_price":25.29,"expiration_date":"2026-11-07","underlying":"Common Stock","underlying_shares":834},"source":{"system":"sec-edgar","filing":"0001209191-18-009012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118009012/doc4.xml","form_type":"4"}},{"id":4068124,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-09T19:27:23.000Z","date":"2018-02-08","kind":"sale","acquired":false,"shares":3497,"price":85.77,"value":299937.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":93771,"source":{"system":"sec-edgar","filing":"0001209191-18-009012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118009012/doc4.xml","form_type":"4"}},{"id":4068123,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-09T19:27:23.000Z","date":"2018-02-08","kind":"exercise","acquired":true,"shares":2663,"price":20.76,"value":55283.88,"ownership":{"direct":true},"balance_after":97268,"source":{"system":"sec-edgar","filing":"0001209191-18-009012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118009012/doc4.xml","form_type":"4"}},{"id":4068122,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-09T19:27:23.000Z","date":"2018-02-08","kind":"exercise","acquired":true,"shares":834,"price":25.29,"value":21091.86,"ownership":{"direct":true},"balance_after":94605,"source":{"system":"sec-edgar","filing":"0001209191-18-009012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118009012/doc4.xml","form_type":"4"}},{"id":4068121,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-09T19:27:23.000Z","date":"2018-02-07","kind":"tax_withholding","acquired":false,"shares":2700,"price":85.49,"value":230823.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":93771,"source":{"system":"sec-edgar","filing":"0001209191-18-009012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118009012/doc4.xml","form_type":"4"}},{"id":4078471,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-02T19:26:46.000Z","date":"2018-02-01","kind":"exercise","acquired":false,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested and became exercisable on November 1, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":93294,"derivative":{"exercise_price":51.76,"expiration_date":"2025-10-31","underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001209191-18-007206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118007206/doc4.xml","form_type":"4"}},{"id":4078470,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-02T19:26:46.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":4167,"price":85.78,"value":357445.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":96471,"source":{"system":"sec-edgar","filing":"0001209191-18-007206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118007206/doc4.xml","form_type":"4"}},{"id":4078469,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-02T19:26:46.000Z","date":"2018-02-01","kind":"exercise","acquired":true,"shares":4167,"price":51.76,"value":215683.92,"ownership":{"direct":true},"balance_after":100638,"source":{"system":"sec-edgar","filing":"0001209191-18-007206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118007206/doc4.xml","form_type":"4"}},{"id":4078468,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-02T19:26:46.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":25639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018."}],"balance_after":96471,"source":{"system":"sec-edgar","filing":"0001209191-18-007206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118007206/doc4.xml","form_type":"4"}},{"id":4090770,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-24T18:46:37.000Z","date":"2018-01-22","kind":"exercise","acquired":false,"shares":102539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested and became exercisable on November 1, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":97461,"derivative":{"exercise_price":51.76,"expiration_date":"2025-10-31","underlying":"Common Stock","underlying_shares":102539},"source":{"system":"sec-edgar","filing":"0001209191-18-005228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118005228/doc4.xml","form_type":"4"}},{"id":4090769,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-24T18:46:37.000Z","date":"2018-01-22","kind":"sale","acquired":false,"shares":102539,"price":86.25,"value":8843988.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":70832,"source":{"system":"sec-edgar","filing":"0001209191-18-005228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118005228/doc4.xml","form_type":"4"}},{"id":4090768,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-24T18:46:37.000Z","date":"2018-01-22","kind":"exercise","acquired":true,"shares":102539,"price":51.76,"value":5307418.64,"ownership":{"direct":true},"balance_after":173371,"source":{"system":"sec-edgar","filing":"0001209191-18-005228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118005228/doc4.xml","form_type":"4"}},{"id":4094314,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-19T21:00:30.000Z","date":"2018-01-17","kind":"exercise","acquired":false,"shares":26633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":101208,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":26633},"source":{"system":"sec-edgar","filing":"0001209191-18-004661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118004661/doc4.xml","form_type":"4"}},{"id":4094313,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-19T21:00:30.000Z","date":"2018-01-17","kind":"exercise","acquired":false,"shares":2498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":30836,"derivative":{"exercise_price":25.29,"expiration_date":"2026-11-07","underlying":"Common Stock","underlying_shares":2498},"source":{"system":"sec-edgar","filing":"0001209191-18-004661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118004661/doc4.xml","form_type":"4"}},{"id":4094312,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-19T21:00:30.000Z","date":"2018-01-17","kind":"sale","acquired":false,"shares":7990,"price":69.95,"value":558900.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":70832,"source":{"system":"sec-edgar","filing":"0001209191-18-004661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118004661/doc4.xml","form_type":"4"}},{"id":4094311,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-19T21:00:30.000Z","date":"2018-01-17","kind":"sale","acquired":false,"shares":21141,"price":68.1,"value":1439702.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":78822,"source":{"system":"sec-edgar","filing":"0001209191-18-004661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118004661/doc4.xml","form_type":"4"}},{"id":4094310,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-19T21:00:30.000Z","date":"2018-01-17","kind":"exercise","acquired":true,"shares":26633,"price":20.76,"value":552901.08,"ownership":{"direct":true},"balance_after":99963,"source":{"system":"sec-edgar","filing":"0001209191-18-004661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118004661/doc4.xml","form_type":"4"}},{"id":4094309,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-01-19T21:00:30.000Z","date":"2018-01-17","kind":"exercise","acquired":true,"shares":2498,"price":25.29,"value":63174.42,"ownership":{"direct":true},"balance_after":73330,"source":{"system":"sec-edgar","filing":"0001209191-18-004661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919118004661/doc4.xml","form_type":"4"}},{"id":4124720,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-12-20T16:37:57.000Z","date":"2017-12-18","kind":"sale","acquired":false,"shares":1816,"price":44.96,"value":81647.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":70832,"source":{"system":"sec-edgar","filing":"0001209191-17-066652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117066652/doc4.xml","form_type":"4"}},{"id":4167192,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-11-09T19:32:34.000Z","date":"2017-11-08","kind":"tax_withholding","acquired":false,"shares":684,"price":55.98,"value":38290.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":72648,"source":{"system":"sec-edgar","filing":"0001209191-17-060099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117060099/doc4.xml","form_type":"4"}},{"id":4172329,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-03T19:30:58.000Z","date":"2017-11-02","kind":"exercise","acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option became vested and exercisable on December 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter."}],"balance_after":33334,"derivative":{"exercise_price":25.29,"expiration_date":"2026-11-07","underlying":"Common Stock","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001209191-17-059331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117059331/doc4.xml","form_type":"4"}},{"id":4172328,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-11-03T19:30:58.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":6666,"price":54.95,"value":366296.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales and related option exercises reported on this Form 4 were executed pursuant to a trading plan adopted by the reporting person on March 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934."}],"balance_after":73332,"source":{"system":"sec-edgar","filing":"0001209191-17-059331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117059331/doc4.xml","form_type":"4"}},{"id":4172327,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-11-03T19:30:58.000Z","date":"2017-11-02","kind":"exercise","acquired":true,"shares":6666,"price":25.29,"value":168583.14,"ownership":{"direct":true},"balance_after":79998,"source":{"system":"sec-edgar","filing":"0001209191-17-059331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117059331/doc4.xml","form_type":"4"}},{"id":4182321,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-10-20T20:24:44.000Z","date":"2017-10-20","kind":"grant","acquired":true,"shares":35893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards (\"RSAs\") granted pursuant to the 2014 Equity Incentive Plan. The RSAs will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date:\n\nUp to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the \"FDA\") of JCAR017 in any indication within certain designated timeframes (the \"JCAR017 Milestone\"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement.\n\nUp to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes."}],"balance_after":73332,"source":{"system":"sec-edgar","filing":"0001209191-17-057692","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117057692/doc4.xml","form_type":"4"}},{"id":4208959,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-09-14T19:31:05.000Z","date":"2017-09-13","kind":"sale","acquired":false,"shares":12850,"price":44.95,"value":577607.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":37439,"source":{"system":"sec-edgar","filing":"0001209191-17-052872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117052872/doc4.xml","form_type":"4"}},{"id":4220459,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-08-31T19:44:42.000Z","date":"2017-08-29","kind":"sale","acquired":false,"shares":12869,"price":39.95,"value":514116.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":50289,"source":{"system":"sec-edgar","filing":"0001209191-17-050959","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117050959/doc4.xml","form_type":"4"}},{"id":4283563,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-06-13T16:37:01.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":13927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Approximately 75% of each Restricted Share Unit (\"RSU\") represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances."}],"balance_after":13927,"derivative":{"underlying":"Common Stock","underlying_shares":13927},"source":{"system":"sec-edgar","filing":"0001209191-17-039492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117039492/doc4.xml","form_type":"4"}},{"id":4360783,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit (RSU)","published_at":"2017-04-04T17:43:02.000Z","date":"2017-04-03","kind":"grant","acquired":true,"shares":12437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Approximately 75% of the RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances."}],"balance_after":12437,"derivative":{"underlying":"Common Stock","underlying_shares":12437},"source":{"system":"sec-edgar","filing":"0001209191-17-025181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117025181/doc4.xml","form_type":"4"}},{"id":4459138,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-09T19:31:56.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":127841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":127841,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":127841},"source":{"system":"sec-edgar","filing":"0001209191-17-009286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117009286/doc4.xml","form_type":"4"}},{"id":4459137,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-02-09T19:31:56.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":27439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017."}],"balance_after":63158,"source":{"system":"sec-edgar","filing":"0001209191-17-009286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919117009286/doc4.xml","form_type":"4"}},{"id":4560333,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-10T20:56:49.000Z","date":"2016-11-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option become vested and exercisable on December 8, 2016 and 1/48th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":40000,"derivative":{"exercise_price":25.29,"expiration_date":"2026-11-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-16-149491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919116149491/doc4.xml","form_type":"4"}},{"id":4560332,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-11-10T20:56:49.000Z","date":"2016-11-10","kind":"sale","acquired":false,"shares":12921,"price":24.135,"value":311848.335,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 was effected pursuant to an Issuer approved Rule 10b5-1 compliant sell-to-cover award, in order to cover tax withholding incident to the vesting of 38,640 RSUs.  The number of shares sold to cover such withholding obligations was determined based on the trade price, which is equal to the average of the high and low prices of the Issuer's common stock on November 2, 2016, the next trading day following the date on which the RSUs vested."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sale reported on this Form 4 was effected pursuant to an Issuer approved Rule 10b5-1 compliant sell-to-cover award, in order to cover tax withholding incident to the vesting of 38,640 RSUs.  The number of shares sold to cover such withholding obligations was determined based on the trade price, which is equal to the average of the high and low prices of the Issuer's common stock on November 2, 2016, the next trading day following the date on which the RSUs vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale reported on this Form 4 was effected pursuant to an Issuer approved Rule 10b5-1 compliant sell-to-cover award, in order to cover tax withholding incident to the vesting of 38,640 RSUs.  The number of shares sold to cover such withholding obligations was determined based on the trade price, which is equal to the average of the high and low prices of the Issuer's common stock on November 2, 2016, the next trading day following the date on which the RSUs vested."}],"balance_after":35719,"source":{"system":"sec-edgar","filing":"0001209191-16-149491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919116149491/doc4.xml","form_type":"4"}},{"id":4560331,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-11-10T20:56:49.000Z","date":"2016-11-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of November 8, 2016."}],"balance_after":48640,"source":{"system":"sec-edgar","filing":"0001209191-16-149491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1594864/000120919116149491/doc4.xml","form_type":"4"}}]}